Abeona Therapeutics Inc Forward P/E
What is the Forward P/E of Abeona Therapeutics Inc?
The Forward P/E of Abeona Therapeutics Inc is -1.35
What is the definition of Forward P/E?
Forward price to earnings ratio is the ratio of a company’s stock price to the company’s estimated earnings per share for the next twelve months.
The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.
Forward P/E of companies in the Health Care sector on NASDAQ compared to Abeona Therapeutics Inc
What does Abeona Therapeutics Inc do?
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
Companies with forward p/e similar to Abeona Therapeutics Inc
- Editas Medicine Inc has Forward P/E of -1.41
- Torstar has Forward P/E of -1.40
- Sutro Biopharma Inc has Forward P/E of -1.38
- Genprex Inc has Forward P/E of -1.37
- LL Flooring Inc has Forward P/E of -1.36
- CHF Solutions Inc has Forward P/E of -1.36
- Abeona Therapeutics Inc has Forward P/E of -1.35
- Spero Therapeutics Inc has Forward P/E of -1.35
- Aerpio Pharmaceuticals has Forward P/E of -1.34
- Bionano Genomics Inc has Forward P/E of -1.32
- Bio-Path Inc has Forward P/E of -1.29
- Chimerix Inc has Forward P/E of -1.29
- DBV Technologies SA has Forward P/E of -1.29